Lysophosphatidic acids in cerebrospinal fluids: Potential biomarkers and therapeutic targets for neuropathic pain

抄録

Recent advances in lipidomics have allowed for the measurement of precise levels of biologically active lipids in clinical human samples, which can aid us in understanding the involvement of bioactive lipids in the pathogenesis of human diseases. Among the various human diseases, a variety of membrane lipid-derived mediators have been demonstrated to possess important roles in the initiation, maintenance, and modulation of neuropathic pain (NP). Lysophosphatidic acid (LPA) has been identified as being the main initiator of NP based on experimental animal models, as well as clinical studies using a lipidomics approach. Currently, there is no specific medical treatment and no objective laboratory testing for NP. Based on these conditions, we have described the possible implementation of inhibitors of autotaxin, a producing enzyme for LPA, and LPA measurements in the cerebrospinal fluid (CSF) as a therapeutic target and a potential diagnostic marker.